PsA Treatment With hOKT3γ1 (Ala-Ala)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Arthritis, Psoriatic

In brief

hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.

Key facts

Study ID

NCT00239720

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

4

Starts

2006-03-16

Expected to finish

2008-06-25

Last updated by the study team

2017-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of psoriatic arthritis. Participants do not need to have concurrent psoriasis to participate in the study;
• Active inflammation in 3 or more joints;
• Currently receiving ongoing therapy with methotrexate or azathioprine; and
• Willing to use acceptable forms of contraception.

You may not qualify if…

• Active infection with HIV, hepatitis C virus, or hepatitis B virus;
• Uncompensated heart failure or a recent myocardial infarction (heart attack) within the 6 months prior to study entry;
• Certain other serious illnesses or cancers;
• Participation in another clinical trial within the 6 weeks prior to study entry; or
• Pregnant or breastfeeding.

Where it is running

• University of Colorado — Aurora, Colorado, United States
• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.